Gastric Cancer
Gastric Cancer
Advertisement
Emily MenendezGastric Cancer | May 17, 2024
Bemarituzumab is a humanized monoclonal antibody that is selective for FGFR2b.
Read More
Nilay Sethi, MD, PhDGastric Cancer | May 13, 2024
Dr. Sethi continues his comments on NER deficiency in gastric cancer cell lines in response to cisplatin treatment.
Nilay Sethi, MD, PhDGastric Cancer | May 13, 2024
Dr. Sethi discusses homologous recombination and nucleotide excision repair pathways in DNA repair for cancers.
Jordi Rodón Ahnert, MD, PhDGastric Cancer | May 7, 2024
Dr. Rodón Ahnert compares the differences of sacituzumab tirumotecan use in the second- vs third-line setting for patients.
Katy MarshallGastric Cancer | May 3, 2024
The final results from the KEYNOTE-811 trial will determine if Keytruda will receive continued approval from the FDA.
Katy MarshallGastric Cancer | April 30, 2024
HERCESSI was developed by Accord BioPharma, Inc., the US specialty division of Intas Pharmaceuticals Ltd.
Emily MenendezGastric Cancer | April 24, 2024
Surgical resection with curative intent is the primary therapy for gastric cancer, yet the 5-year survival rate is just 20%.
Emily MenendezGastric Cancer | April 19, 2024
Patients with a DpR of ≥30% had a favorable survival time with nivolumab monotherapy as a later-line treatment.
Katy MarshallGastric Cancer | April 19, 2024
For those with a PD-L1 CPS of 5 or higher who received the combination therapy, the median OS was not achieved.
Katy MarshallGastric Cancer | April 19, 2024
Researchers investigated the potential of an anti-H Pylori treatment after radical gastrectomy to improve survival.
Emily MenendezGastric Cancer | April 19, 2024
Individuals with MLH1, MSH2, and EpCAM PVs were found to have a higher risk of developing GC and DC at the age of 70 years.
Yelena Janjigian, MDGastroesophageal Cancer | April 19, 2024
Dr. Janjigian discusses how the agent - created with invariant natural killer t-cells - works in tandem with other therapies.
Yelena Janjigian, MDGastric Cancer | April 19, 2024
Dr. Janjigian describes the history behind nivolumab treatment, and the differences in initial results versus follow-up.
Zachary BessetteGastroesophageal Cancer | February 21, 2024
Results of the PANDA study show that atezo has an additive effect with chemo in eliciting tumor response in early G/GEJ.
Katy MarshallGastroesophageal Cancer | February 9, 2024
The study investigated if avelumab and paclitaxel plus ramucirumab would constitute an effective second-line treatment.
Yelena Janjigian, MDASCO GI 2024 | January 25, 2024
Dr. Yelena Janjigian discusses the results of the phase 3 MATTERHORN study at ASCO GI 2024.
Emily MenendezASCO GI 2024 | January 23, 2024
At ASCO GI 2024, new research examined several treatment combinations to determine which combination may improve OS rates.
Emily MenendezASCO GI 2024 | January 23, 2024
The combination of neoadjuvant/adjuvant pembrolizumab with FLOT is a feasible treatment with no new safety concerns.
Katy MarshallGastric Cancer | January 23, 2024
The benefits of combination neoadjuvant and adjuvant chemotherapy and immune checkpoint inhibition are currently unknown.
Katy MarshallGastric Cancer | December 14, 2023
Researchers sought to determine if a combination of sintilimab and first-line chemotherapy would improve survival rates.
Advertisement
Advertisement
Advertisement
Latest News

May 17, 2024